العربية

Briefing · UAE · Healthcare and AI · 17 November 2026

Abu Dhabi's AI Clinician Framework: an invitation to research, not a licence to practise

The Department of Health – Abu Dhabi has published a framework for AI systems that would do work reserved for licensed clinicians. Headlines call it an authorisation pathway. The document calls itself exploratory. Vendors should plan on the document.

What happened

On 20 October 2026 the Department of Health – Abu Dhabi announced an AI Clinician Framework at the Abu Dhabi Future Health Summit and published Version 1.0 of the document. The Department describes it as setting out how AI clinician systems may ultimately be authorised to perform clinical activities that would otherwise need a licensed clinician.

What the document says about itself

The published text is titled an exploratory framework. Its opening status statement says its purpose is to support preliminary market engagement, research dialogue and the exploration of possible future opportunities. It says in terms that it does not establish an authorisation or a licence, and that any future activity is at the Department's discretion and subject to applicable law, internal approvals, technical and clinical evaluation, and separate written arrangements.

That is a narrower thing than much of the coverage suggests. Nothing in it lets an AI system practise today.

How a proposal is assessed

Section 4 says an AI Clinician research proposal is assessed on two dimensions: clinical scope and demonstrated competence. Clinical scope is subject to DoH approval and sets what the system may be evaluated against. The Department's announcement adds that a wider scope needs stronger evidence of competence, and that safeguards, including physician oversight, apply at every level of scope.

What this does not change

  • The Responsible AI Standard still governs AI that licensed entities develop, buy or deploy. Our briefing for vendors sets out what it asks.
  • Research involving patients still goes through the Department's research review route.
  • ADHICS and health-data law apply to any system that touches patient data, whatever it is called.

What is worth doing now

  • Do not describe a product as DoH-authorised or licensed on the strength of this framework.
  • If you want to take part, frame it as a research proposal. Define the clinical scope narrowly and bring evidence of competence for that scope.
  • Have your Responsible AI Standard evidence ready first. A partner hospital will ask for it before it sponsors any study.
  • If you run a hospital, treat an AI clinician pilot as research and route it through research governance, not through procurement alone.

The question for your board

Are we describing any AI product, ours or a supplier's, as approved by a regulator, and can we show the document that says so?

This briefing summarises the document's status statement and section 4. Read the full text before acting on it.